文献速递消化系统肿瘤

转移性结直肠癌一线奥沙利铂联合靶向治疗的生存随时间改善:ARCAD数据库研究

Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.
PubMed 文献 · Eur J Cancer · 2025-10-02

该研究基于ARCAD数据库13项随机对照试验的5424例患者个体数据,分析2004-2017年间接受一线奥沙利铂化疗联合靶向治疗的转移性结直肠癌患者生存变化。结果显示中位总生存从2004-2008年的21.4个月延长至2009-2013年的28.6个月和2014-2017年的29.7个月,无进展生存和进展后生存也呈类似改善趋势,多因素分析证实治疗时期是独立预后因素。

要点

  • 一线奥沙利铂联合靶向治疗转移性结直肠癌的中位总生存从21.4个月改善至29.7个月
  • 左半肿瘤和RAS野生型肿瘤总生存改善明显,右半或RAS突变肿瘤获益有限
  • 后续治疗使用增加贡献了进展后生存的延长

核心结论

  • 转移性结直肠癌患者接受一线奥沙利铂化疗联合分子靶向治疗的生存结局随时间逐步改善。
  • 治疗时期是总生存和无进展生存的独立预后因素。
  • 左半和RAS野生型肿瘤总生存改善明显,右半或RAS突变肿瘤获益有限。

研究设计与样本

  • 基于ARCAD数据库的个体患者数据荟萃分析。
  • 纳入2004至2017年间13项随机对照试验的5424例患者。
  • 患者接受奥沙利铂化疗联合贝伐珠单抗或抗EGFR抗体。
  • 按2004-2008、2009-2013、2014-2017三个时间段分析。

主要发现

  • 中位总生存从21.4个月(2004-2008)延长至28.6个月(2009-2013)和29.7个月(2014-2017)。
  • 无进展生存和进展后生存呈类似改善趋势。
  • 多因素分析证实治疗时期是总生存和无进展生存的独立预后因素。
  • 亚组分析显示左半肿瘤和RAS野生型肿瘤总生存改善,右半或RAS突变肿瘤获益有限。
  • 后续治疗使用增加贡献了进展后生存的延长。

临床怎么用

  • 支持一线奥沙利铂联合靶向治疗作为转移性结直肠癌的标准方案。
  • 强调生物标志物驱动治疗策略的重要性。
  • 关注后续治疗在优化临床结局中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The combination of oxaliplatin-based doublet chemotherapy and molecular targeted agents is the standard first-line treatment for metastatic colorectal cancer. However, the temporal evolution of associated treatment outcomes is unclear. We utilized Aide et Recherche en Cancérologie Digestive (ARCAD) data to evaluate the chronological changes in clinical outcomes associated with this regimen in metastatic colorectal cancer. METHODS: An individual patient data meta-analysis was performed using data from 5424 patients enrolled in 13 randomized controlled trials within the ARCAD database between 2004 and 2017. Eligible patients received oxaliplatin-based chemotherapy combined with bevacizumab or anti-epidermal growth factor receptor antibodies. Intervals of 2004-2008, 2009-2013, and 2014-2017 were examined. Overall, progression-free, and post-progression survivals were analyzed using Kaplan-Meier and Cox proportional hazards models adjusted for key prognostic factors. RESULTS: Median overall survival improved over time, from 21.4 months (2004-2008) to 28.6 months (2009-2013) and 29.7 months (2014-2017). Similar trends were observed for progression-free and post-progression survivals. Multivariable analysis confirmed the treatment period as an independent prognostic factor for overall and progression-free survivals. Subgroup analyses revealed improvements in overall survival for left-sided and RAS wild-type tumors, whereas minimal gains were found for right-sided or RAS-mutated tumors. Increased use of subsequent therapies contributed to prolonged post-progression survival. CONCLUSIONS: We demonstrated progressive improvements in survival outcomes for patients with metastatic colorectal cancer receiving first-line oxaliplatin-based chemotherapy plus molecular targeted agents. The findings highlight the importance of biomarker-driven treatment strategies and the evolving role of subsequent therapies in optimizing clinical outcomes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yamamoto K, Bando H, Misumi T, et al. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. Eur J Cancer. 2025. PMID: 41056789. doi:10.1016/j.ejca.2025.116034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。